Douglas Spriggs, MD
Interventional Cardiology · Clearwater, FLNPI 1811986698
Payments from drug & device makers
Across 1,450 payments — averaging $2191.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.5M
- Medtronic$630K
- Amgen$233K
- Novo Nordisk AS$227K
- CSL Behring$207K
- Janssen Research & Development, LLC$95K
- plus $305K from 26 others
Across 3 payments — averaging $7750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$23K
- Novo Nordisk AS$100
What the payments were for
- Travel & lodging$2,37141%
- Food & beverage$3,35858%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $1,481,644 |
| Medtronic(2 entities) | 154 | $629,921 |
| Amgen | 30 | $232,674 |
| Novo Nordisk AS | 421 | $226,713 |
| CSL Behring | 77 | $206,877 |
| Janssen Research & Development, LLC | 20 | $94,735 |
| Edwards Lifesciences | 24 | $76,033 |
| Esperion Therapeutics, Inc. | 155 | $76,001 |
| Biotronik Inc. | 417 | $58,018 |
| Bayer | 21 | $44,072 |
| Baxter Healthcare | 9 | $37,824 |
| Eli Lilly | 3 | $6,695 |
| Bard Peripheral Vascular, Inc. | 1 | $4,450 |
| AstraZeneca | 43 | $866 |
| Boston Scientific | 9 | $346 |
| Abiomed | 4 | $254 |
| Abbott | 4 | $149 |
| Penumbra, Inc. | 1 | $100 |
| Sanofi-aventis U.S. LLC | 5 | $84 |
| E.r. Squibb & Sons, L.L.C. | 6 | $84 |
| Pfizer | 4 | $65 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $49 |
| Chiesi USA, Inc. | 4 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Biosense Webster, Inc. | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Shockwave Medical, Inc | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Angiodynamics, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,177,936 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 261 | $289,884 |
| CamzyosMavacamten | 12 | $96,690 |
| Repatha SureclickEvolocumab | 96 | $92,237 |
| EntrestoSacubitril/Valsartan | 50 | $69,283 |
| XareltoRivaroxaban | 56 | $67,681 |
| JardianceEmpagliflozin | 17 | $26,660 |
| OzempicSemaglutide | 14 | $18,022 |
| BrilintaTicagrelor | 18 | $16,654 |
| FarxigaDapagliflozin Propanediol | 20 | $13,563 |
| Praluent PenAlirocumab | 15 | $10,155 |
| NexlizetBempedoic Acid/Ezetimibe | 15 | $7,412 |
| Rosuvastatin Calcium | 595 | $7,280 |
| Atorvastatin Calcium | 427 | $5,223 |
| Ezetimibe | 193 | $4,238 |
| VascepaIcosapent Ethyl | 11 | $3,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $65 | $289,884261 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $84 | $96,69012 claims |
| NovartisEntresto | $1,481,644 | $69,28350 claims |
| Johnson & JohnsonXarelto | $11 | $67,68156 claims |
| AstraZenecaBrilinta, Farxiga | $866 | $30,21838 claims |
| Boehringer IngelheimJardiance | $15 | $26,66017 claims |
| Esperion Therapeutics, Inc.Nexlizet | $76,001 | $7,41215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Clearwater
- Syed GilaniClearwater$511K
- Bernardo SteinClearwater$337K
- Dominick AngiolilloJacksonville$4M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.